Elevated glucagon-like peptide-1 plasma levels, as a possible adaptive response, in diabetic NOD mice

Biochemical and Biophysical Research Communications

Volumn 423, Issue 3, 2012, Pages 583-587

  Rydgren, T ^a   Borjesson A ^a   Carlsson, A ^b   Sandler, S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Mercodia AB ^*  (Sweden)

Author keywords

Alpha cells; Beta cells; Glucagon like peptide 1; Islets; NOD mouse; Type 1 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INSULIN; MICE; MICE, INBRED NOD; PANCREAS;

ANIMALIA; MUS;

EID: 84863304470     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.011     Document Type: Article

References (24)

1. Bach J.F. Insulin-dependent diabetes mellitus as a beta-cell targeted disease of immunoregulation. J. Autoimmun. 1995, 8:439-463.
2. Sandler S., Andersson A.K., Barbu A., Hellerström C., Holstad M., Karlsson E., Sandberg J.O., Strandell E., Saldeen J., Sternesjö J., Tillmar L., Eizirik D.L., Flodström M., Welsh N. Novel experimental strategies to prevent the development of type 1 diabetes mellitus. Ups. J. Med. Sci. 2000, 105:17-34.
3. Mojsov S., Heinrich G., Wilson I.B., Ravazzola M., Orci L., Habener J.F. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 1986, 261:11880-11889.
4. Drucker D.J., Asa S. Glucagon gene expression in vertebrate brain. J. Biol. Chem. 1988, 263:13475-13478.
5. Mojsov S., Kopczynski M.G., Habener J.F. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J. Biol. Chem. 1990, 265:8001-8008.
6. Tang-Christensen M., Vrang N., Larsen P.J. Glucagon-like peptide containing pathways in the regulation of feeding behavior. Int. J. Obes. Relat. Metab. Disord. 2001, (Suppl. 5):S42-S47.
7. Kilimnik G., Kim A., Steiner D.F., Friedman T.C., Hara M. Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic α-cells in mouse models of β-cell regeneration. Islets 2010, 2:149-155.
8. Whalley N.M., Pritchard L.E., Smith D.M., White A. Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?. J. Endocrinol. 2011, 211:99-106.
9. Holst J.J. Enteroglucagon. Annu. Rev. Physiol. 1997, 59:257-271.
10. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80:952-957.
11. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
12. Beinborn M., Worrall C.I., McBride E.W., Kopin A.S. A human glucagon-like peptide-1 receptor polymorphism result in reduced agonist responsiveness. Regul. Pept. 2005, 130:1-6.
13. Tomas E., Habener J.F. Insulin-like actions of glucagon-like peptide-1 a dual receptor hypothesis. Trends Endocrinol. Metab. 2010, 21:59-67.
14. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007, 113:546-593.
15. Berghöfer P., Peterson R.G., Schneider K., Fehmann H.C., Göke B. Incretin hormone expression in the gut of diabetic mice and rats. Metabolism 1997, 46:261-267.
16. Kikutani H., Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 1992, 51:285-322.
17. Atkinson M.A., Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat. Med. 1999, 5:601-604.
18. A. Carlsson, M. Simonsson, R. Boman, M. Eberlein, P Lindstedt, Relevance of sample collection method and specificity for the quantification of GLP-1 in two new ELISA assays for active and total GLP-1, Diabetologia 53 (Suppl. 1) (2010) (A859 Abstract).
19. Anderson M.S., Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 2005, 23:447-485.
20. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
21. Tourrel C., Bailbé D., Meile M.J., Kergoat M., Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001, 50:1562-1570.
22. Wang Q., Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002, 45:1263-1273.
23. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003, 278:471-478.
24. Zhang J., Tokui Y., Yamagata K., Kozawa J., Sayama K., Iwahashi H., Okita K., Miuchi M., Konya H., Hamaguchi T., Namba M., Shimomura I., Miyagawa J.I. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 2007, 50:1900-1909.